A drop in first time home buyers weighed the markets down during the midday with the Dow slipping 10 points to 17,856. Nasdaq lost 14 points to 5,127.
On the upside
Infosonics (Nasdaq: IFON) narrowed losses for the third quarter as revenue climbed.
Eyegate Pharmaceuticals (Nasdaq: EYEG) reported upbeat interim data from an ongoing Phase 1b/2a clinical trial of EGP-437 opthalmic solution in patients with macular edema.
Constellium (NYSE: CSTM) fell to a loss for the third quarter but revenue rose.
On the downside
EnerNOC (Nasdaq: ENOC) disappointed with sharply lower third quarter earnings and revenue that fell short of expectations.
Bluebird bio (NYSE: BLUE) widened losses significantly as revenue plunged and the company released abstracts indicating mixed results for its LentiGoblin BB305 gene therapy.
Third quarter earnings plunged for ExamWorks Group (NYSE: EXAM).
In the broad market, advancing issues outpaced decliners by a margin of more than 10 to 9 on the NYSE while decliners edged out advancers by by nearly 5 to 4 on Nasdaq. The broader S&P 500 slipped 2 points to 2,100. Bitcoin rose $8 to $402.
